• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Footnote

Footnote.co

Showcasing research with the power to change our world

  • Facebook
  • Twitter
Footnote
  • About
  • Contributors
  • Partner With Us
  • Press
  • Projects
  • Academia
  • Business
  • Education
  • Government
  • Health
  • International
  • Science
  • Society
  • Technology
Research Review

A Birth-Control Pill For Men?

Jesse Lyons, MITSeptember 20, 2012April 5, 2017
Sections
  • Health
  • Science
Topics
  • Birth Control
  • Gender
  • Health Technology
  • Pharmacology
  • Pregnancy
  • Sexual Health

There are many methods of contraception available for those of us who are interested in baby-making without making babies. For women, forms of birth control include hormones, physical barriers, and intrauterine devices. For men, the options are fewer and include barriers (condoms), semi-permanent solutions (vasectomy), and old-timey methods such as withdrawal and testicular warming.(a)

Developing reliable male birth control that is as simple as popping the female birth-control pill has been a holy grail of sorts in contraception research. Currently, there are clinical trials for hormonal male birth control in the U.S., while in India, researchers are testing a cheap, semi-permanent, reversible, injectable gel that kills sperm as it passes through the vas deferens. Adding to these approaches, a recent Cell paper out of James Bradner’s lab at the Dana Farber Cancer Center in Boston describes a drug that appears to provide efficient, reversible, non-hormonal contraception in male mice.1

The Bradner group’s main focus is cancer therapeutics, particularly the targeting of proteins that interact with DNA. It turns out that one of the compounds they developed as an anti-cancer treatment (JQ1), also inhibits a protein that has been identified through genetic studies as a key regulator of male fertility. In their latest paper, the researchers tested whether JQ1 could function as a male contraceptive. The results look very promising. Mice treated with the drug showed decreased sperm count and motility.(b) When male mice undergoing treatment with JQ1 were allowed to mate, a once daily low-dose treatment prevented pregnancy in about half of the mice. Contraception was successful in the rest of the mice following prolonged twice-daily administration.(c) An ideal contraceptive should not only be highly effective but also reversible, and JQ1 was successful in this regard. Mice that had been on JQ1 for several months successfully sired pups one to two months after they were taken off the drug.

Functionally, JQ1 seems to possess all the attributes of an excellent contraceptive for men. It is effective, reversible and does not interfere with hormone levels or mating behavior. Right now, the main drawback seems to be administration of the drug, which required twice daily injections in some of the mice. The Bradner group is working on JQ1 derivatives that have stronger selectivity and availability. Hopefully, these derivatives will be amenable to less invasive methods of administration and we will see them in clinical trials in the near future.

Related


  1. The Fight To End HIV In Children
  2. kids playing video games
    Can Video Games Make Kids Healthier?
  3. DNA double helixes
    Unlocking Cancer’s Genetic Secrets

Endnotes

  1. M.M. Matzuk, M.R. McKeown, P. Filippakopoulos, Q. Li, L. Ma, J.E. Agno, M.E. Lemieux, S. Picaud, R.N. Yu, J. Qi, S. Knapp, J.E. Bradner (2012) “Small-Molecule Inhibition of BRDT for Male Contraception,” Cell, 150(4): 673-684.

Sidenotes

  • (a) A vasectomy involves blocking the tubes that carry sperm. It is permanent (unless intentionally reversed) and is almost 100% effective, though in rare cases (1 in 1,000) the tubes can grow back and begin working again.
  • (b) Motility means movement. Sperm that can’t swim can’t reach the egg and can’t make a baby.
  • (c) Although the drug was 100% effective when given twice a day, the trial was small, involving only seven mice treated over a period of 6 months. Further study would be needed to demonstrate that the treatment works consistently in all mice.

sidebar

Contributed by

Jesse Lyons

Jesse Lyons


Jesse Lyons is a senior scientist at Torque Therapeutics, where he develops immunotherapies to treat cancer. He previously worked as a postdoctoral researcher in Systems Biology at MIT and Massachusetts General Hospital, using computational approaches to understand the interactions between the immune system, gut bacteria, and epithelium in mouse models of Inflammatory Bowel Disease. Jesse received his Ph.D. in Biomedical Sciences and Cancer Biology from the University of California San Francisco, where he studied the connections between red hair, the cell cycle, and melanoma. He also received a B.S. in Biochemistry from Columbia University.

Footer

About Footnote

Footnote is an online media company that increases the impact of academic knowledge by making it accessible and engaging for new audiences.

Learn more about Footnote and our contributors.

Follow us on Facebook and Twitter.

Partner with us to increase the impact of your research.

Sections

  • Academia
  • Business
  • Education
  • Government
  • Health
  • International
  • Science
  • Society
  • Technology

Projects

  • Babson College
  • The Collaborative
  • Genomic Medicine
  • Making Research Reliable
  • Robotics
  • Works Cited Podcast

© 2025 Footnote